The National Cancer Control Authority in Libya has announced a significant medical achievement with the production of the “NAF” compound.
This substance is used in positron emission tomography (PET) scans to diagnose bone tumours with exceptional accuracy, surpassing traditional nuclear imaging techniques.
The breakthrough was achieved through collaboration with Tripoli University Hospital and Al-Sada Company.
According to a statement on the Authority’s Facebook page on Friday, this development marks a major advancement in bone disease diagnostics, providing highly precise results to help doctors determine optimal treatment options for patients.
The Authority expressed gratitude to Al-Sada Company for its key role in enabling this new technology.
The company supplied operational materials, advanced equipment, and training for medical staff at Tripoli University Hospital. This collaboration between public and private sectors demonstrates Libya’s capacity to adopt and implement global medical innovations.
Director of the National Cancer Control Authority, Haider Al-Saeh, praised the accomplishment, stating, “This is a new milestone, and more progress is coming.”
Al-Saeh had previously revealed that over 22,000 people in Libya are currently battling cancer.
